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Background: O’Neill’s recent Review on Antimicrobial Resistance expressed the view that by 2020 high-income
countries should make it mandatory to support antimicrobial prescribing with rapid diagnostic evidence
whenever possible.
Methods: Routine microbiology diagnosis of 95 respiratory specimens from patients with severe infection were
compared with those generated by the Unyvero P55 test, which detects 20 pathogens and 19 antimicrobial
resistance markers. Supplementary molecular testing for antimicrobial resistance genes, comprehensive culture
methodology and 16S rRNA sequencing were performed.
Results: Unyvero P55 produced 85 valid results, 67% of which were concordant with those from the routine
laboratory. Unyvero P55 identiﬁed more potential pathogens per specimen than routine culture (1.34 vs. 0.47
per specimen). Independent veriﬁcation using 16S rRNA sequencing and culture (n = 10) corroborated 58% of
additional detections compared to routine microbiology. Overall the average sensitivity for organism detection
by Unyvero P55 was 88.8% and speciﬁcity was 94.9%. While Unyvero P55 detected more antimicrobial re-
sistance markers than routine culture, some instances of phenotypic resistance were missed.
Conclusions: The Unyvero P55 is a rapid pathogen detection test for lower respiratory specimens, which iden-
tiﬁes a larger number of pathogens than routine microbiology. The clinical signiﬁcance of these additional
organisms is yet to be determined. Further studies are required to determine the eﬀect of the test in practise on
antimicrobial prescribing and patient outcomes.
1. Introduction
We are entering a new era in the diagnosis of infectious diseases,
where rapid, molecular-biology based methods sit alongside traditional
culture based techniques. Fast and accurate diagnosis of infections is
crucial if we are to achieve evidence-based antimicrobial prescribing
and improved antimicrobial stewardship. The recent O’Neill Review on
Antimicrobial resistance recommended that by 2020, antimicrobial
prescriptions in high-income countries should be made only when
supported by rapid diagnostic evidence, where such tests are available
[1]. The past ﬁve years have seen an explosion in DNA-based tests for
bacterial infections, many of which run on ‘sample-in, answer-out’
platforms requiring minimal hands on time and user training. While
many such tests have been applied to the diagnosis of blood-stream
infections [2–4], a number of tests for other clinical syndromes such as
respiratory tract infections [5] or gastrointestinal infections [6] also
exist. Some manufacturers oﬀer not only pathogen detection, but also
detection of selected antimicrobial resistance determinants, such as
mecA or carbapenemases [2,7]. These tests provide much faster turn
around times than conventional methods and prompt possibilities for
improved patient outcomes and better antimicrobial stewardship [8,9].
Many tests now detect not only bacterial pathogens but also selected
antimicrobial resistance genes. However, studies designed to measure
impact on such outcomes remain rare.
One such test is the recently introduced Curetis Unyvero P55
pneumonia cartridge [10]. Pneumonia is responsible for signiﬁcant
mortality and morbidity world-wide [11] and is the second most
common cause of adult hospitalization in the US after child birth [12]
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as well as a leading indication for antimicrobial prescriptions [13]. It
can be either community-acquired (CAP) or hospital-acquired (HAP)
with a subset of HAP patients suﬀering from ventilator-associated
pneumonia (VAP). The P55 test uses multiplex PCR and microarray
detection to identify 20 causative agents of severe lower respiratory
tract infections (LRTIs) and 19 antibiotic resistance determinants
straight from clinical specimens (Table 1). The turn-around time is
around 5 h, with minimal hands on time (approx. 2 min).
Here, we evaluated the performance of the Unyvero P55 test on 95
specimens from hospitalized patients with severe LRTIs and compared
the results to routine microbiology. Veriﬁcation of a subset of results
was carried out using 16S rRNA sequencing and a more comprehensive
culture based method.
2. Materials and methods
2.1. Ethics
We adhered to a Governance framework with an overarching ethics
agreement for the UCL Infection DNA Bank (Reference: 12/LO/1089),
relating to the use of patient specimens surplus to clinical needs and
anonymised patient data.
2.2. Specimen collection and analysis
We collected anonymised respiratory specimens surplus to clinical
requirements from adult in-patients with pneumonia at the Royal Free
hospital (RFH) and University College London Hospital (UCLH), from
June to September 2015. Duplicate specimens from the same patient
were excluded unless collected>6 days apart or diﬀerent aetiology
was found [14]. Fresh specimens (< 48 h old) with radiological con-
ﬁrmation of pneumonia, were processed with the Unyvero P55 Pneu-
monia assay as per manufacturer’s instructions. Brieﬂy, 180 μL of spe-
cimen are placed in the sample tube and inserted into the Lysator
instrument, which performs mechanical and chemical sample lysis and
homogenisation in approximately 30 min. The sample tube is then
transferred into a test cartridge, which is inserted into the Analyzer
module, which performs DNA puriﬁcation, multiplex PCR and micro-
array detection of amplicons. Results are available in approximately
4h30 min. Detailed information of the system and method can be found
on the manufacturer’s website [10].
2.3. Microbiological analysis
Results were compared to those obtained by the routine clinical
microbiology laboratories of the two participating hospitals as pre-
viously described [15]. A more comprehensive analysis, as described
previously [15], was also performed in order to verify the presence of
resistance genes and study discrepancies between routine culture and
Unyvero P55. Brieﬂy, a sweep of growth was taken from the primary
culture of the specimen on chocolate agar (CHOC), stored in Micro-
bank™ vials at −80 °C, and both 10 μL of the undiluted broth medium
and a 10−5 dilution in saline solution, were cultured onto CHOC, Co-
lumbia Blood agar, Brilliance UTI agar and Columbia colistin-nalidixic
acid agar (Oxoid). All colony types of diﬀerent morphologies were
identiﬁed and analysed using MALDI-TOF (Biotyper version 3.1 soft-
ware).
Susceptibility to beta-lactam antibiotics was evaluated using the
disc diﬀusion method on Mueller-Hinton agar following EUCAST re-
commendations [16]. Cefoxitin (30 μg) discs were used for identiﬁca-
tion of potential methicillin resistant S. aureus (MRSA). Ciproﬂoxacin
susceptibility testing was performed on P. aeruginosa and E. coli, using
the gradient diﬀusion method (Etest®, Biomérieux), interpreted ac-
cording to EUCAST guidelines. Double disc diﬀusion for detection of
beta-lactamases was performed using ROSCO Diagnostica kits ac-
cording to manufacturer’s instructions.
2.4. 16S rRNA sequencing
For nucleic acid extractions, 400 μL of specimen were heat killed at
95 °C for 30 min, 300 μL were transferred to a GeneOhm™ Lysis bead
tube (BD) and bead beaten in a Biospec Bead Beater at 3500 oscillations
per min for 30s. Nucleic acids were extracted from 200 μL of recovered
supernatant using ZR Viral RNA/DNA kit (Zymo research) following
manufacturer’s instructions, and eluted in 50 μL of sterile water.
Nucleic acid extracts were quantiﬁed using a Qubit 2.0 ﬂuorometer
(Thermoﬁsher Scientiﬁc, US) and diluted to 20 μg/L Samples were
ampliﬁed using LightCycler 480 ProbesMaster (Roche) PCR mastermix
with forward (5′ TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGC
CTACGGGNGGCWGCAG 3′) and reverse (5′ GTCTCGTGGGCTC-
GGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC 3′) pri-
mers (Sigma-Aldrich) designed to amplify hypervariable regions V3 and
V4 of the bacterial 16S gene while also adding sequencing adapters.
The PCR products were cleaned as per manufacturer’s instructions
using Agencourt AMPure XP beads (Beckman Coulter) and then un-
derwent further limited PCR (8 cycles) to attach Illumina sequencing
adapters and Nextera Indexing before a ﬁnal clean up step. The ﬁnal
PCR products underwent further analysis using 2200 Tapestation
bioanalyser (Agilent Technologies, US) to assess amplicon purity and
size (approx. 630 bp) and were quantiﬁed using Qubit 2.0 ﬂuorometer.
The molar concentration of each sample was calculated and a 4 nM
ﬁnal concentration was used.
Sequencing was performed using the Illumina MiSeq Platform ac-
cording to manufacturer’s instructions (Illumina, US) [17] and output
was analysed using the 16 s rRNA sequencing analysis pipeline in
BaseSpace (Illumina, US). Identiﬁed organisms were reported to the
genus level and those that contributed to> 0.5% of the total number of
matches were considered in the analysis.
2.5. Molecular detection of resistance mechanisms
For molecular detection of resistance genes as described previously
[15], DNA extraction of resistant bacteria was performed using QIAmp
DNA Mini Kit (Qiagen) following manufacturer’s instructions. Isolates
with suspected presence of beta-lactamases were tested using the
Check-MDR CT103XL test (Checkpoints, NL) for molecular detection
and identiﬁcation of genes encoding carbapenemase, AmpC and ESBL
enzymes. All suspected ESBL and carbapanemase positive isolates were
Table 1
Pathogens and resistance markers detected by Unyvero P55. Resistance markers considered during our analyses are in bold.
Gram-positive Bacteria Gram-Negative Bacteria Fungus Resistance genes
Staphylococcus aureus Acinetobacter baumannii, Escherichia coli, Haemophilus inﬂuenzae, Klebsiella
oxytoca, Klebsiella kneumoniae, Klebsiella variicola, Moraxella catarrhalis,
Morganella morganii, Pseudomonas aeruginosa, Serratia marcescens,
Stenotrophomonas maltophilia, Legionella pneumophila, Mycoplasma pneumoniae
Enterobacter cloacae complex, Enterobacter aerogenes, Proteus spp.
Pneumocystis
jirovecii
blaCTX-M, ermB, GyrA83, GyrA87, blaKPC, blaoxa-
23 blaoxa-24 blaoxa-48 blaoxa-58 blaTEM, blaSHV,
mecA, mecC sul1
Streptococcus
pneumoniae
Citrobacter freundii blaIMP, blaVIM, blaNDM
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conﬁrmed by PCR (HotStar Taq Mastermix, Qiagen). The presence of
mecA among suspected MRSA and the quinolone resistance-determining
regions (QRDR) of the gyrA and parC genes from ﬂuoroquinolone re-
sistant E. coli or P. aeruginosa were ampliﬁed by PCR. All PCR amplicons
were sent for DNA sequencing using the Sanger method at Beckman
Coulter Genomics and analysed using BioNumerics (Applied Maths)
software and NCBI’s BLAST. All primers used in this study are listed in
Table S1 [15].
3. Results
A total of 95 respiratory clinical specimens from hospital inpatients
with pneumonia were collected from June to September 2015 from two
tertiary hospitals in London. Specimens were tested using the Unyvero
P55 Pneumonia assay (Unyvero P55) and results were compared to
routine clinical microbiology tests. Ten specimens did not generate a
valid result and were excluded from further analysis; 9 were due to test
failures (1 machine failure and 8 partial system failures where one or
more chambers failed) and 1 where there was a problem with the
mastermix. The remaining 85 specimens consisted of 52 sputa, 31en-
dotracheal tubes (ETT) aspirates and 1 bronchoalveolar lavage (BAL);
the vast majority of the specimens came from patients with HAP
(n = 44), while 14 and 27 specimens were from VAP and CAP patients
respectively.
3.1. Pathogen detection
The mean turnaround time from specimens received to results from
the routine laboratory was 53 h (range 21h–166 h). One or more sig-
niﬁcant organisms were reported by routine microbiology for 35 spe-
cimens (41%) while ‘normal respiratory ﬂora’ (NRF), ‘non-signiﬁcant
growth’ (NSG) or ‘mixed growth of doubtful signiﬁcance’ (MGODS)
were reported for 47 specimens (55%), and 3 specimens produced no
growth. On the other hand, Unyvero P55 identiﬁed at least one pa-
thogen in 57 specimens (67%) and was negative for 28 specimens in-
cluding the 3 that produced no growth (Fig. 1). Overall, routine mi-
crobiology reported 0.47 signiﬁcant organisms/specimen whereas
Unyvero P55 detected 1.34. The most common organisms reported by
the culture laboratory were P. aeruginosa (n = 11), H. inﬂuenzae
(n = 7) and S. maltophilia (n = 5) whereas the most common organisms
detected by Unyvero P55 were P. aeruginosa (n = 23), S. maltophilia
(n = 20), and E. coli (n = 15) (Table 2).
Results from Unyvero P55 and standard microbiology culture were
concordant in 57 specimens (67%) (Fig. S1). Of these, Unyvero P55
identiﬁed the same organism (s) as routine culture in 12 specimens, and
the same pathogen and at least one additional organism in 18 speci-
mens. Negative results given by both tests were concordant in 27 spe-
cimens. Discordant occurred in the remaining 28 specimens, including
24 reported as NRF, NSG or MGODS by the microbiology laboratory
where Unyvero P55 detected speciﬁc organisms. Unyvero P55 produced
four false-negatives, speciﬁcally S. pneumoniae in 2 cases, H. inﬂuenzae
in one, and a further single specimen containing S. maltophilia by cul-
ture but reported by Unyvero P55 as E. coli. Approximately 55% of
samples were reported to contain normal respiratory ﬂora by the clin-
ical laboratory whereas Unyvero P55 reported an organism in the
majority of samples, leading to ‘false positive’ results. We calculated
overall average sensitivity for Unyvero P55 as 88.8% and overall
average speciﬁcity as 94.9% (Table 2).
Fig. 1. Distribution of the number of micro-organisms detected per specimen.
Table 2
Frequency of organisms detected by routine microbiology and Unyvero P50 (n = 85 specimens). Negative specimens include those classiﬁed by routine microbiology as NRF, NSG,
MGODS or no growth.
Group Target
Organism
Routine
laboratory
UnyVero P55 True Positive
(Routine and
Unyvero P55)
False Positive
(Unyvero P55
only)
False Negative
(Routine only)
Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
Gram-positive S. aureus 4 9 4 5 0 100.0 93.8 44.4 100.0
S. pneumoniae 3 3 1 2 2 33.3 97.6 33.3 97.6
Non-fermenters A. baumannii 0 3 0 3 0 – 96.5 – 100.0
P. aeruginosa 11 23 11 12 0 100.0 83.8 47.8 100.0
H. inﬂuenzae 7 12 6 6 1 85.7 92.3 50.0 98.6
M. catarrhalis 1 3 1 2 0 100.0 97.6 33.3 100.0
S. maltophilia 5 20 4 16 1 80.0 80.0 20.0 98.5
Enterobacteriaciae E. cloacae
complex
0 4 0 4 0 – 95.3 – 100.0
E. aerogenes 0 1 0 1 0 – 98.8 – 100.0
E. coli 3 15 3 12 0 100.0 85.4 20.0 100.0
K. pneumoniae 3 7 3 4 0 100.0 95.1 42.9 100.0
K. oxytoca 0 2 0 2 0 – 97.6 – 100.0
K. variicola 0 0 0 0 0 – 100.0 – 100.0
M. morganii 0 0 0 0 0 – 100.0 – 100.0
Proteus spp 0 2 0 2 0 – 97.6 – 100.0
S. marcescens 1 7 1 6 0 100.0 92.9 14.3 100.0
C. koseri 1 N/A N/A N/A N/A N/A N/A – –
C. freundii 0 1 0 1 0 – 98.8 – 100.0
Atypical bacteria L. pneumophila 0 0 0 0 0 – 100.0 – 100.0
M. pneumoniae 0 0 0 0 0 – 100.0 – 100.0
Fungi C. albicans 1 N/A N/A N/A N/A N/A N/A – –
P. jirovecii 0 2 0 2 0 – – – 100.0
Negative 50 28
Overall (average) 88.8 94.9
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3.2. Detection of antimicrobial resistance
The routine clinical microbiology laboratories reported a total of 39
organisms (Table S2), 31% of these were fully susceptible while 69%
were resistant to one or more antimicrobial classes and 38% multi-re-
sistant (MDR) (deﬁned as resistance to ≥3 antimicrobials of diﬀerent
classes) [18]. The Unyvero P55 test is capable of detecting 17 antibiotic
resistance markers with many of them highly prevalent among both
pathogenic and commensal bacterial populations19 resulting in 72% of
specimens reported to contain at least one resistance marker, including
14 specimens where no organism was detected.
We therefore restricted our analysis to ESBLs, carbapenemases,
presumptive MRSA, and ﬂuoroquinolone resistance (FQR) among E. coli
and P. aeruginosa only (Table 3), as these are clinically signiﬁcant re-
gardless of host (ESBLs and carbapenemases) or can be attributed to a
particular organism with reasonable reliability (MRSA and FQR).
Therefore, blaTEM, blaSHV, ermB and sul1 were excluded from further
analysis. Unyvero P55 identiﬁed 18 occurrences of relevant resistance
markers (resistance marker associated with a relevant organism), whilst
routine microbiology identiﬁed relevant resistance phenotypes in 10
isolates (Table 3).
Four P. aeruginosa isolates resistant to carbapenems were not de-
tected by Unyvero P55. The routine laboratory reported ﬂuor-
oquinolone resistance for one E. coli and three P. aeruginosa isolates
whereas Unyvero P55 identiﬁed 5 E. coli and 7 P. aeruginosa with gyrA
mutations. Supplementary analysis of 3 E. coli isolates and 4 P. aerugi-
nosa isolates (some of which were retrieved using the comprehensive
culture method) conﬁrmed the presence of ﬂuoroquinolone resistance
and gyrA mutations in all but one of the P. aeruginosa studied. parC
mutations were also identiﬁed by PCR in the three E. coli and two P.
aeruginosa isolates (Table 3) The remaining 2 E. coli and 3 P. aeruginosa
could not be retrieved for further study. Four putative MRSA positive
specimens (S. aureus+ mecA) were detected by Unyvero P55, two of
which were reported as MSSA by the routine laboratory, 1 as K. pneu-
moniae and 1 as NRF. During further analyses, S. aureus isolates were
recovered from all four specimens but lacked the MRSA phenotype and
were PCR negative for mecA. Unyvero P55 identiﬁed two specimens
with blaCTX-M, one specimen containing K. pneumoniae (conﬁrmed as
blaCTX-M-15 positive using Checkpoints) and one specimen containing E.
coli that routine microbiology reported as containing S. maltophilia. A
further blaCTX-M producing E. coli isolate identiﬁed by routine micro-
biology and conﬁrmed by Checkpoints microarray was not detected by
Unyvero P55.
3.3. Additional analysis by 16S rRNA sequencing and comprehensive
culture
We used additional methods in an attempt to resolve discordance
between Unyvero P55 and results from routine microbiology. 16S rRNA
(V3-V4) sequencing direct from sputum specimens was performed on
14 randomly selected specimens to study the diversity and relative
abundance of bacteria within the specimens (Table 4, Fig. S2). Those
where a single pathogen was reported by routine culture tended to have
single dominant pathogen detected by 16S rRNA sequencing. Those
reported as normal ﬂora by routine culture consisted of a diverse
mixture of bacteria according to the sequencing data as expected. This
suggested broad agreement of NGS with routine culture rather than
Unyvero P55. Ten of the 14 also underwent comprehensive culture
analysis whereby all organisms growing on the primary chocolate agar
plate were systematically catalogued and identiﬁed. Considering these
10 specimens, routine culture detected 5 pathogens, Unyvero P55 de-
tected 17 and 16S and comprehensive culture detected 10 each. Five
pathogens detected by Unyvero P55 were not conﬁrmed by any other
method. They included three instances of S. maltohphilia detection, one
A. baumannii complex and one S. marcescens.
4. Discussion
The laboratory diagnosis of lower respiratory tract infections is
primarily culture-based, producing slow and possibly insensitive re-
sults. This is the ﬁrst study to assess the performance and potential
clinical utility of the Curetis Unyvero P55 Pneumonia test, a point-of-
care sample-in answer-out test, with a turnaround time of 5 h. This is
signiﬁcantly faster than the average turn around time by the routine
laboratories (53 h in this study).
The Unyvero P55 test replaces the previously evaluated P50 assay
[15], with a revised panel and improved performance for some in-
dividual assays. The composition of the resistance panel for P55 is in
our opinion much improved compared to P50, making interpretation of
results simpler. However, we observed a relatively high failure rate
(10.5%), with one total machine failure, 8 partial failures (i.e. when 1
or more chambers fail) and 1 reagent failure. This is similar to the
failure rate of 12.6% observed in our hands for the P50 test [15] and
thus remains an area for the manufacturer to improve upon.
Sensitivity of pathogen detection was good, with all but 4 of the
pathogens reported by routine microbiology detected by P55. The
number of positive samples was too low to enable us to comment on the
performance of individual assays. As expected of a molecular test, the
P55 had considerably more pathogen detection calls than routine cul-
ture, both in specimens reported as normal ﬂora only and specimens
containing organisms considered signiﬁcant. Interestingly, two of the
additional detections were P. jirovecii, a recognized pathogen not rou-
tinely tested unless speciﬁcally requested by the clinician. However, the
clinical relevance of these results remains to be determined as these
infected patients have an atypical presentation being able to produce
sputum [20]. P jirovecii’s potential for causing disease in the im-
munosuppressed is clear; this organism, however, is also known to be
present in lower numbers as a coloniser immunocompetent individuals,
where it causes no disease whatsoever [21]. In both cases where this
result was obtained, further investigation revealed immunosuppression
in the patients concerned but no clear indications for requesting a P.
jirovecii test.
Additional detection of organisms can be expected for a PCR am-
pliﬁcation based test when applied to a clinical specimen from a non-
sterile site such as the respiratory tract or the GI tract, and has been
reported in other studies. [6,22] However, it can be diﬃcult to de-
termine whether additional organisms detected by molecular assays are
signiﬁcant or not. We performed further tests on a small number ran-
domly selected specimens in an attempt to determine their true mi-
crobiological composition and verify whether additional Unyvero P55
detections resulted from a genuine presence of these organisms. We
tested for both viable organisms (comprehensive culture) and presence
Table 3
Number of potentially signiﬁcant resistance mechanisms detected by routine microbiology versus Unyvero P55.
ESBL producer MRSA Fluoroquinolone resistance Carbapenem resistance
Routine Microbiology + Checkpoints/PCR n = 2 blaCTX-M none detected n = 4 1 x E. coli, 3 x P. aeruginosa n = 4 4 x P. aeruginosa, no enzyme detected
Unyvero P55 n = 2 blaCTX-M n = 4a(mecA+S. aureus) n = 12 7 x P. aeruginosa 5 x E. coli n = 0
Concordance 1/2 0/4 3/12 no
a We presumed potential presence of MRSA when both S. aureus and mecA or mecC were detected in the specimen.
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of DNA (16S rRNA sequencing), and were able to corroborate 58% of
additional detections compared to routine culture. On the whole, both
16S rRNA sequencing results and comprehensive culture results more
closely resembled routine microbiology results than those produced by
Unyvero P55. Three of the ﬁve unconﬁrmed detections were S. mal-
tophilia. Indeed, among all specimens, Unyvero P55 detected 20 in-
stances of S. maltophilia, while the routine laboratory reported only 5,
suggesting an issue with the speciﬁcity of this assay. These results are
preliminary but suggest that 16S rRNA sequencing is be a good sup-
plementary molecular technique for resolving discrepancies between
sputum culture and molecular results and may also prove be a good test
for the diagnosis of LRTIs in its own right.
The ability of the Unyvero P55 test to detect antimicrobial re-
sistance was variable. For ease of interpretation and clinical sig-
niﬁcance, four of the markers on the P55 panel were excluded from
analysis, as they are ubiquitous among both pathogens and commensal
ﬂora of the respiratory tract [19]. For ESBLs, Unyvero P55 detected two
instances of the blaCTX-M, one of which was missed by routine culture.
Routine microbiology on the other hand detected another blaCTX-M that
was not picked up by Unyvero P55. Four specimens contained mecA and
S. aureus which suggested presence of MRSA but all were conﬁrmed as
MSSA; as the mecA assay of Unyvero P55 is not species speciﬁc, it is
likely that detected mecA originated from coagulase-negative staphy-
lococci instead [23]. Therefore this assay should not be used for a de-
ﬁnitive diagnosis but may be a useful tool for identifying patients who
should undergo an MRSA screen. Unyvero P55 reliably detected
ﬂuoroquinolone resistance in E. coli and P. aeruginosa. Routine culture
identiﬁed four ﬂuoroquinolone resistant organisms, three of which
were conﬁrmed by Unyvero P55, which in addition identiﬁed a further
9 instances of FQR in specimens where signiﬁcant E. coli or P. aeruginosa
were not identiﬁed by routine culture. No carbapenemases were de-
tected in this set of specimens using either method; however, routine
culture identiﬁed four carbapenem-resistant P. aeruginosa, which did
not produce carbapenemase. It is likely that resistance in these isolates
was porin and/or eﬄux related, frequent resistance mechanisms in this
species [24]. To the best of our knowledge, rapid molecular tests to
detect such mutations are not currently available. This prompts reason
for caution for interpreting molecular resistance results for P. aerugi-
nosa, as lack of carbapenemase genes does not imply phenotypic sus-
ceptibility.
Table 4
Comparison of Unyvero P55 results of 14 random specimens with routine culture, 16S rRNA sequencing and comprehensive culture. For 16S rRNA sequencing results, pathogenic genera
accounting for more than 0.5% of individual reads are reported individually, for commensals, genera accounting for more than 10% of reads are reported. Unyvero P55 results +/++/+
++ readings by the instrument, which give an indication of quantity, are reported. ETT − endotracheal tube aspirate; SPU − sputum.
Specimen number & type Routine Culture Result Unyvero P55 Result Comprehensive Culture 16S rRNA Sequencing Results
346 ETT P. aeruginosa (+++) P. aeruginosa Pseudomonas spp. 38.4%
P. aeruginosa S. marcescens (+++) S. marcescens Streptococcus spp. (not including S. pneumoniae) 17.1%
S. aureus (++) S. aureus Neisseria spp. 16.4%
S. maltophilia (++) Serratia spp. 12.5%
Stenotrophomonas spp 1.6%
Others 14.0%
347 ETT P. aeruginosa (+++) P. aeruginosa Pseudomonas spp. 79.6%
P. aeruginosa Others 20.4%
348 SPU E. coli (+++) Not tested Streptococcus spp. (not including S. pneumoniae) 27.7%
Non signiﬁcant growth P. aeruginosa (++) Lactobacillus spp. 20.1%
K. pneumoniae (+) Pseudomonas spp. 5.1%
M. catarrhalis (+) Escherichia spp. 1.3%
Proteus spp. (+) Others 45.8%
349 SPU No growth Negative Not tested Commensal genera only
350 SPU Normal respiratory ﬂora A. baumannii complex (+) Bacillus cereus Streptococcus spp. (not including S. pneumoniae) 50.0%
Rothia muciloginosa Rothia spp. 13.7%
Others 36.3%
351 ETT Normal respiratory ﬂora Negative Negative Pseudomonas sp. 0.81%
Mixed commensal genera
353 ETT S. maltophilia S. maltophilia (+++) Not tested Stenotrophomonas spp. 95.7%
E. coli (+++) Pseudomonas sp. 0.71%
H. inﬂuenzae (+) Others 4.3%
355 ETT Normal respiratory ﬂora Negative S. haemolyticus Neisseria spp. 22.5%
Prevotella spp. 13.5%
Aggregatibacter spp.11.6%
Haemophilus spp. 11.0%
Others 41.4%
357 SPU K. pneumoniae K. pneumoniae (+++) Not tested Klebsiella spp. 57.5%
Veionella spp. 13.6%
Others 28.9%
358 ETT P. aeruginosa P. aeruginosa (++) P. aeruginosa Pseudomonas spp. 77.2%
S. maltophilia (++) Stenotrophomonas spp.0.6%
Others 22.8%
360 ETT Normal respiratory ﬂora S. maltophilia (++) S. maltophilia Acinetobacter spp. 3.4%
Pseudomonas spp. 1.2%
Mixed commensal genera
374 ETT Normal respiratory ﬂora S. aureus (+++) S. S. aureus Staphylococcus spp. 35.5%
maltophilia (++) Lactobacillus spp. 43.8%
Others 20.7%
376 SPU P. aeruginosa P. aeruginosa (++) P. aeruginosa Pseudomonas spp. 77.5%
S. maltophilia (++) Stenotrophomonas spp. 1.6%
Others 20.9%
377 ETT P. aeruginosa P. aeruginosa (+++) P. aeruginosa Pseudomonas spp. 38.7%
S. maltophila (++) S. aureus Streptococcus spp. (not including S. pneumoniae) 10.8%
S. marcescens (++) E. faecium Acinetobacter spp. 1.0%
S. aureus (+) Others 49.5%
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5. Conclusions
It is usually recognized that up to 70% culture tests fail to identify
an aetiological agent due to existence of unknown pathogens, lack of
accuracy and sensitivity in testing methods and failure of organisms to
recover from antimicrobial therapy [25,26]. Our results showed that a
causative agent was identiﬁed by routine microbiology in 41% of the
specimens as opposed to more sensitive molecular tests such as Unyvero
P55 where 67% were had an organism identiﬁed. This by deﬁnition
challenges the concept of a culture-based “gold standard” by which any
alternative detection technology might be judged. On the whole the test
detects pathogens in a much larger proportion of specimens than rou-
tine culture, however, the clinical signiﬁcance of these ﬁndings remains
to be determined. Conﬁrmatory testing failed to support the presence
some additional organisms, pointing to possible speciﬁcity errors. In-
terpretation of antimicrobial resistance genes detection is complicated
by uncertainty surrounding the host organism of the resistance genes,
and discrepancies between phenotypic and genotypic resistance. This
brief laboratory evaluation suggests larger evaluation studies are
needed, incorporating systematic additional veriﬁcation tests such as
16S rRNA sequencing in order to control for the imperfect gold stan-
dard posed by routine microbiology. If promising, such studies should
be followed with randomized controlled clinical trials to assess the
impact of Unyvero P55 on antimicrobial prescribing and patient out-
comes.
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